Detalhe da pesquisa
1.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Cancer
; 126(6): 1264-1273, 2020 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31860140
2.
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Cancer
; 124(2): 306-314, 2018 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28960265
3.
Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Cancer
; 123(13): 2561-2569, 2017 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28464280
4.
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Haematologica
; 102(4): 719-727, 2017 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28034990
5.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
Lancet Haematol
; 7(2): e122-e133, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31837959
6.
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.
Blood Adv
; 4(13): 3136-3140, 2020 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-32649766